Member Info for bailiff

Hi HBD.....she never knew about the SAR shares being retained. she thought they had been sold but were tucked away in an ISA.....

She's in Auckland NZ but if i had my way the moon would be too near.......

@hotblack Des. Mrs B is no longer part of the equation and now resides with her new meal ticket in Auckland! Win win!

Hold on to the side rails…….

It's been a while but I have redeveloped the 'itch' in my left spherical like when we went from 1p to 9p old money..........

a sign from above?

Just tried £50k, £25k, £10K AND £5K but no shares available to buy through Halifax............

This is now an absolute goldmine for those lucky enough to have bought or are thinking about buying now. Just one piece of good news will rocket this back up to where it belongs. Gla LTHs

Other than to make a quick profit on the wrap issue I don’t understand why some are selling when there is such huge potential for a massive multi bagger here. Each to their own I guess……..

Nice!

Anyone able to say what L2 is looking like?

Wtg

To be expected but i suspect much more to come with some good news......I am holding still and have increased that holding 3 fold since the drop. good luck all......x

# of Trades 113

Vol Sold 78,579

Vol Bought 1,714,500

Bust , not just.

Fiavius. Without the hedging we would have been just as it was a requirement for the continued support from the backers….

Learn your history before typing to avoid looking a bit silly pal.

Hedging is reducing as we speak generating higher fcf. Now if you are long then enjoy the ride. If you’re not then take your drivel elsewhere.

# of Trades 212

Vol Sold 891,479

Vol Bought 2,041,27

So, Halifax don't participate in 'retail offers' (learn something new every day) so does anyone know a way I can participate in the wrap?

Halifax dont have details........

I trade through Halifax but cant see how to get an application in. any ideas?

Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has completed a conditional fundraise of up to £1.5 million (before expenses), via the issue of a total of up to 15,000,000 new ordinary shares of 1.25 pence each in the capital of the Company ("Ordinary Shares") at a price of 10 pence per new

Ordinary Share (the "Placing Price") (the "Fundraise").

The Fundraise will comprise the issue, at the Placing Price, of: · 9,550,000 new Ordinary Shares via a placing (the "Placing Shares") through the Company's broker, Hybridan LLP (the "Placing"); · up to 2,255,000 new Ordinary Shares via a direct subscription (the "Subscription Shares") by certain high net worth individuals (the "Subscription"); · 195,000 new Ordinary Shares via a subscription by certain Directors of the Company (the "Director Subscription"); and · up to 3,000,000 new Ordinary Shares via a retail offering (the "WRAP

Retail Offer") to the Company's existing shareholders, which will be launched shortly, to raise up to £300,000.

In addition, the Company will issue, based on the Placing Price, 576,698 new

Ordinary Shares in lieu of amounts owed to certain Directors from historically deferred salaries (the "Salary Conversion Shares") and 450,000 new Ordinary

Shares to certain advisers to settle amounts due in respect of professional fees (the "Adviser Fee Shares").

As a result of the Fundraise, 1,106,986 warrants over new Ordinary Shares that have been issued to RiverFort Global Opportunities PCC Ltd ("Riverfort") as part of the drawdowns to date under the Equity Prepayment Facility (as announced on 3 August 2023), have had their exercise price rebased to the

Placing Price in accordance with the terms of the agreement entered into at the time of the Equity Prepayment Facility. The Company does not intend to make any further withdrawals pursuant to the Equity Prepayment Facility with

RiverFort.

Use of Proceeds and Cash Preservation

The net proceeds from the Fundraise are intended to be used by the Company to complete Phase 1a clinical studies on its SDC-1801 TYK2/JAK1 inhibitor ("Phase 1a") and, together with the receipt of anticipated R&D tax credits in the amount of £0.7 million which is expected in September 2024, for general working capital purposes.

Furthermore, as part of the Company's ongoing steps to minimise its cash utilisation, in addition to the Salary Conversion, the Directors have agreed to defer a portion of their salaries going forward, so as to ensure the completion of Phase 1a clinical trial can be achieved, with topline data from the trial expected in Q2 2024.

Director Subscription, Salary Conversion and Related Party Transactions

Pursuant to the Director Subscription, Tim Mitchell, CEO, and Clive Birch,

Non-Executive Director, intend to participate in the Fundraise, via direct subscriptions of £5,000 and £4,500 respectivel

HOLDINGS PLC. 28 March 2024

Sareum Holdings plc ("Sareum" or the "Company")

WRAP Retail Offer for up to £300,000

Sareum Holdings plc is pleased to announce a retail offer via the Winterflood

Retail Access Platform ("WRAP") to raise up to £300,000 (the "WRAP Retail

Offer") through the issue of new ordinary shares of 1.25 pence each in the capital of the Company ("Ordinary Shares"). Under the WRAP Retail Offer, up to 3,000,000 new Ordinary Shares (the "WRAP Retail Offer Shares") will be made available at a price of 10 pence per new Ordinary Share.

In addition to the WRAP Retail Offer and as announced earlier this morning, the Company is also proposing a fundraise via a placing and subscription of up to 12,000,000 new Ordinary Shares (the "Placing Shares" and, together with the

WRAP Retail Offer Shares, the "New Ordinary Shares") to raise approximately £1,200,000 (before expenses) (the "Placing") at a price of 10 pence per share (the "Placing Price"). Hybridan LLP acted as sole broker to the Placing. The

Placing Price represents a discount of approximately 31 per cent. to the mid-market closing price of an Ordinary Share on 27 March 2024 (being the latest practicable date prior to this announcement). The issue price of the

WRAP Retail Offer Shares is equal to the Placing Price.

A separate announcement has been made regarding the Placing and its terms and sets out the reasons for the Placing and use of proceeds. The proceeds of the WRAP Retail Offer will be utilised in the same way as the proceeds of the

Placing, to complete Phase 1a clinical studies on its SDC-1801 TYK2/JAK1 inhibitor and, together with the receipt of anticipated R&D tax credits in the amount of £0.7m, for general working capital purposes. .

For the avoidance of doubt, the WRAP Retail Offer is not part of the Placing.

Completion of the WRAP Retail Offer is conditional, inter alia, upon the completion of the Placing but completion of the Placing is not conditional on the completion of the WRAP Retail Offer.

The WRAP Retail Offer and the Placing are conditional, inter alia, on the New

Ordinary Shares being admitted to trading on the AIM Market ("AIM") of the

London Stock Exchange plc ("Admission"). It is anticipated that Admission will become effective and that dealings in the New Ordinary Shares will commence on

AIM, at 8:00 a.m. on 5 April 2024.

WRAP Retail Offer

The Company values its retail shareholder base and believes that it is appropriate to provide its existing retail shareholders in the United Kingdom the opportunity to participate in the WRAP Retail Offer.

Therefore, the Company is making the WRAP Retail Offer open to eligible investors in the United Kingdom, being existing shareholders of Sareum, following release of this announcement and through certain financial intermediaries. Existing shareholders can contact their broker or wealth manager to participate in the WRAP Retail Offer.